CORE--CLINICAL PHENOTYPES AND RESOURCES

核心——临床表型和资源

• 批准号: 6110061
• 负责人: JOHN L VANDEBERG
• 金额: $ 34.71万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6110061
• 关键词: atherosclerosis; biomedical facility; blood banks; blood chemistry; blood lipoprotein; cryopreservation; fibrinolysis; human population genetics; human tissue; patient /disease registry; phenotype; sample collection

The overall objective of the Clinical Phenotypes and Resources Core is to serve all projects by maintaining the blood sample collection, by providing clinical phenotype data from lipoprotein and fibrinolysis assays, and by providing statistical analyses of assays done in this core and in Core A. The lipoprotein and fibrinolysis data will be analyzed in Projects 1, 2, and 3 for evidence of genes that affect plasma levels (either mass or function, depending on the measure). White blood cells will be provided to Project 2 for DNA extraction. Blood samples will be processed and catalogued, and the components stored at -80 degreeC. An up- to-date inventory of the remaining volume of each sample will be maintained. Plasma and serum aliquots will be delivered to Program Project investigators and technical staff as needed. Lipoprotein phenotypes to determined on each plasma sample are TG, TC, and HDL-C by clinical chemical techniques; LDL size distribution by nondenaturing gradient gel electrophoresis; and Lp(a) and isoform-specific Lp(a) concentrations. Fibrinolytic phenotypes include plasma concentrations of fibrinogen, tissue type plasminogen activator (t-PA), and fibrin fragment D-dimer; and plasma activity of plasminogen. Quantitative data from blind duplicates will be monitored and evaluated. The investigators in this core will collaborate with investigators in the projects in analyzing data and preparing manuscripts.

临床表型和资源的总体目标 核心是通过维护血液样本来服务所有项目 收集，通过提供脂蛋白的临床表型数据 和纤维蛋白溶解分析，并通过提供统计分析 在此核心和核心A中进行的分析。脂蛋白和 纤维蛋白溶解数据将在项目1、2和3中分析 影响血浆水平的基因的证据（质量或功能， 取决于措施）。 白细胞将被提供 DNA提取的项目2。 血液样本将被处理 并分类，并且成分存储在-80 dgreec。 一个 每个样本剩余卷的及时清单将是 维护。 血浆和血清等分试样将传递到 计划项目调查人员和技术人员根据需要。 在每个血浆样品上确定的脂蛋白表型是 通过临床化学技术TG，TC和HDL-C； LDL尺寸 通过非核梯度凝胶电泳分布；和 LP（A）和同工型特异性LP（A）浓度。 纤维蛋白水解 表型包括血浆浓度的纤维蛋白原，组织类型 纤溶酶原激活剂（T-PA）和纤维蛋白片段D-二聚体；和 纤溶酶原的血浆活性。 盲人的定量数据 将监控和评估重复项。 调查人员在 该核心将与调查人员合作 分析数据并准备手稿。